Burkitt Lymphoma — Subtypes,Pathogenesis, and Treatment Strategies |
| |
| Institution: | 1. Memorial Sloan Kettering Cancer and Weill Cornell Medical College, New York, NY, USA;1. University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;1. University of Leipzig, Medical Clinic I, Hematology and Cellular Therapy, Liebigstr. 22, 04103 Leipzig, Germany;1. The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;1. Institut de Cancérologie Gustave Roussy, Villejuif, France;1. University of Texas MD Anderson Cancer Center, Houston, United States;1. Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14263, USA |
| |
| Abstract: | Burkitt's lymphoma (BL) is a rare and highly aggressive Non-Hodgkin lymphoma (NHL) with a germinal center phenotype, a nearly universal myc oncogene translocation to an enhancer element and a proliferation index greater than 95%.1 Bcl-2 is not expressed as opposed to double-hit or triple-hit lymphoma. Genetic mutations and aberrancy involving the phosphatidylcholine 3-kinase and cyclin-dependent kinase pathways are also involved.2, 3, 4, 5 Rarely patients present with stage I disease and others are considered as high risk if greater than stage I or with elevated LDH or masses greater than 10 cm. |
| |
| Keywords: | Burkitt lymphoma aggressive BL |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
